Mack Katharina, Starz Kathrin, Sauter Daniel, Langer Simon, Bibollet-Ruche Frederic, Learn Gerald H, Stürzel Christina M, Leoz Marie, Plantier Jean-Christophe, Geyer Matthias, Hahn Beatrice H, Kirchhoff Frank
Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Virol. 2017 Feb 28;91(6). doi: 10.1128/JVI.02177-16. Print 2017 Mar 15.
Simian immunodeficiency viruses (SIVs) use their Nef proteins to counteract the restriction factor tetherin. However, a deletion in human tetherin prevents antagonism by the Nef proteins of SIVcpz and SIVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1). To promote virus release from infected cells, pandemic HIV-1 group M strains evolved Vpu as a tetherin antagonist, while the Nef protein of less widespread HIV-1 group O strains acquired the ability to target a region adjacent to this deletion. In this study, we identified an unusual HIV-1 group O strain (RBF206) that evolved Vpu as an effective antagonist of human tetherin. While both RBF206 Vpu and Nef exert anti-tetherin activity in transient-transfection assays, mainly Vpu promotes RBF206 release in infected CD4 T cells. Although mutations distinct from the adaptive changes observed in group M Vpus (M-Vpus) were critical for the acquisition of its anti-tetherin activity, RBF206 O-Vpu potently suppresses NF-κB activation and reduces CD4 cell surface expression. Interestingly, RBF206 Vpu counteracts tetherin in a largely species-independent manner, degrading both the long and short isoforms of human tetherin. Downmodulation of CD4, but not counteraction of tetherin, by RBF206 Vpu was dependent on the cellular ubiquitin ligase machinery. Our data present the first example of an HIV-1 group O Vpu that efficiently antagonizes human tetherin and suggest that counteraction by O-Nefs may be suboptimal. Previous studies showed that HIV-1 groups M and O evolved two alternative strategies to counteract the human ortholog of the restriction factor tetherin. While HIV-1 group M switched from Nef to Vpu due to a deletion in the cytoplasmic domain of human tetherin, HIV-1 group O, which lacks Vpu-mediated anti-tetherin activity, acquired a Nef protein that is able to target a region adjacent to the deletion. Here we report an unusual exception, identifying a strain of HIV-1 group O (RBF206) whose Vpu protein evolved an effective antagonism of human tetherin. Interestingly, the adaptive changes in RBF206 Vpu are distinct from those found in M-Vpus and mediate efficient counteraction of both the long and short isoforms of this restriction factor. Our results further illustrate the enormous flexibility of HIV-1 in counteracting human defense mechanisms.
猿猴免疫缺陷病毒(SIVs)利用其Nef蛋白来对抗限制因子束缚素。然而,人类束缚素中的一个缺失可防止SIVcpz和SIVgor的Nef蛋白产生拮抗作用,这两种病毒代表了人类免疫缺陷病毒1型(HIV-1)的猿类前身。为促进病毒从受感染细胞中释放,HIV-1大流行的M组毒株进化出Vpu作为束缚素拮抗剂,而传播范围较小的HIV-1 O组毒株的Nef蛋白获得了靶向该缺失区域相邻部位的能力。在本研究中,我们鉴定出一株不同寻常的HIV-1 O组毒株(RBF206),它进化出Vpu作为人类束缚素的有效拮抗剂。虽然RBF206的Vpu和Nef在瞬时转染试验中均发挥抗束缚素活性,但主要是Vpu促进RBF206在受感染的CD4 T细胞中释放。尽管与在M组Vpu(M-Vpus)中观察到的适应性变化不同的突变对于其抗束缚素活性的获得至关重要,但RBF206 O-Vpu能有效抑制NF-κB激活并降低CD4细胞表面表达。有趣的是,RBF206 Vpu以很大程度上不依赖物种的方式对抗束缚素,降解人类束缚素的长、短异构体。RBF206 Vpu对CD4的下调而非对束缚素的对抗作用依赖于细胞泛素连接酶机制。我们的数据展示了HIV-1 O组Vpu有效拮抗人类束缚素的首个实例,并表明O组Nefs的对抗作用可能并不理想。先前的研究表明,HIV-1 M组和O组进化出两种不同策略来对抗限制因子束缚素的人类同源物。由于人类束缚素胞质结构域中的一个缺失,HIV-1 M组从Nef转变为Vpu,而缺乏Vpu介导的抗束缚素活性的HIV-1 O组获得了一种能够靶向该缺失区域相邻部位的Nef蛋白。在此我们报告一个不同寻常的例外情况,鉴定出一株HIV-1 O组毒株(RBF206),其Vpu蛋白进化出对人类束缚素的有效拮抗作用。有趣的是,RBF206 Vpu中的适应性变化与在M-Vpus中发现的不同,并介导对这种限制因子的长、短异构体的有效对抗。我们的结果进一步说明了HIV-1在对抗人类防御机制方面具有巨大的灵活性。